metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Androgen deprivation therapy in patients with localized disease: Comparison with...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry
Terapia de privación de andrógenos en pacientes con enfermedad localizada: comparación de las opciones de tratamiento y tiempo hasta la resistencia a la castración. Resultados del Registro Español de Cáncer de Próstata
J. Garcia-Rodrigueza,
Corresponding author
jgrmed@hotmail.com

Corresponding author.
, J.M. Fernandez-Gomeza, J.M. Cozarb, B. Miñanac, F. Gomez-Veigad, A. Rodriguez-Antoline, On behalf of Grupo Español de Cáncer de Próstata (GESCAP) , On behalf of Grupo Español de Cáncer de Próstata (GESCAP)
a Departamento de Urología, Hospital Universitario Central de Asturias, Oviedo, Spain
b Departamento de Urología, Hospital Virgen de las Nieves, Granada, Spain
c Departamento de Urología, Hospital Morales Meseguer, Murcia, Spain
d Departamento de Urología, Hospital Clínico, Salamanca, Spain
e Departamento de Urología, Hospital Universitario 12 de Octubre, Madrid, Spain
Read
3
Times
was read the article
2
Total PDF
1
Total HTML
Share statistics
 array:24 [
  "pii" => "S2173578620300214"
  "issn" => "21735786"
  "doi" => "10.1016/j.acuroe.2020.03.001"
  "estado" => "S300"
  "fechaPublicacion" => "2020-04-01"
  "aid" => "1196"
  "copyright" => "AEU"
  "copyrightAnyo" => "2019"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "fla"
  "cita" => "Actas Urol Esp. 2020;44:156-63"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:19 [
      "pii" => "S0210480619301433"
      "issn" => "02104806"
      "doi" => "10.1016/j.acuro.2019.06.006"
      "estado" => "S300"
      "fechaPublicacion" => "2020-04-01"
      "aid" => "1196"
      "copyright" => "AEU"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "fla"
      "cita" => "Actas Urol Esp. 2020;44:156-63"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Art&#237;culo original</span>"
        "titulo" => "Terapia de privaci&#243;n de andr&#243;genos en pacientes con enfermedad localizada&#58; comparaci&#243;n de las opciones de tratamiento y tiempo hasta la resistencia a la castraci&#243;n&#46; Resultados del Registro Espa&#241;ol de C&#225;ncer de Pr&#243;stata"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "156"
            "paginaFinal" => "163"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Androgen deprivation therapy in patients with localized disease&#58; Comparison with curative intent treatments and time to castration resistance&#46; Results of the Spanish Prostate Cancer Registry"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0025"
            "etiqueta" => "Figura 5"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr5.jpeg"
                "Alto" => 2403
                "Ancho" => 1519
                "Tamanyo" => 199317
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Supervivencia espec&#237;fica del c&#225;ncer en el grupo 2 &#40;tumores de alto riesgo localizados y localmente avanzados&#41; seg&#250;n el tratamiento administrado&#44; incluidos los pacientes del Registro Espa&#241;ol de C&#225;ncer de Pr&#243;stata&#46;</p> <p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">EBT y&#47;o BT&#58; radiaci&#243;n de haz externo y&#47;o braquiterapia&#59; PR&#58; prostatectom&#237;a radical&#59; TPA&#58; terapia de privaci&#243;n de andr&#243;genos&#46;</p>"
            ]
          ]
        ]
        "autores" => array:2 [
          0 => array:2 [
            "autoresLista" => "J&#46; Garcia-Rodriguez, J&#46;M&#46; Fernandez-Gomez, J&#46;M&#46; Cozar, B&#46; Mi&#241;ana, F&#46; Gomez-Veiga, A&#46; Rodriguez-Antolin"
            "autores" => array:7 [
              0 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Garcia-Rodriguez"
              ]
              1 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Fernandez-Gomez"
              ]
              2 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Cozar"
              ]
              3 => array:2 [
                "nombre" => "B&#46;"
                "apellidos" => "Mi&#241;ana"
              ]
              4 => array:2 [
                "nombre" => "F&#46;"
                "apellidos" => "Gomez-Veiga"
              ]
              5 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Rodriguez-Antolin"
              ]
              6 => array:1 [
                "colaborador" => "en representaci&#243;n del Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata &#40;GESCAP&#41;"
              ]
            ]
          ]
          1 => array:2 [
            "autoresLista" => ""
            "autores" => array:1 [
              0 => array:1 [
                "colaborador" => "En representaci&#243;n del del Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata &#40;GESCAP&#41;"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2173578620300214"
          "doi" => "10.1016/j.acuroe.2020.03.001"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578620300214?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480619301433?idApp=UINPBA00004N"
      "url" => "/02104806/0000004400000003/v2_202006090719/S0210480619301433/v2_202006090719/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2173578620300202"
    "issn" => "21735786"
    "doi" => "10.1016/j.acuroe.2019.11.002"
    "estado" => "S300"
    "fechaPublicacion" => "2020-04-01"
    "aid" => "1221"
    "copyright" => "AEU"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Urol Esp. 2020;44:164-71"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Role of the neutrophil&#47;lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "164"
          "paginaFinal" => "171"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Papel del &#237;ndice neutr&#243;filo&#47;linfocito en pacientes con c&#225;ncer de pr&#243;stata resistente a castraci&#243;n metast&#225;sicos tratados en primera l&#237;nea con abiraterona"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1292
              "Ancho" => 2082
              "Tamanyo" => 97958
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Progression-free survival curve according to NLR prior to treatment&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "D&#46; Nieblas-Toscano, A&#46;J&#46; Arenas-Bonilla, J&#46;F&#46; Flores-Mart&#237;n, F&#46; Guti&#233;rrez-Tejero, C&#46; Velarde-Mu&#241;oz, C&#46;I&#46; Ramos-Alaminos, M&#46;C&#46; Salas-Moreno, R&#46; Galisteo-Moya, J&#46; Moreno-Jim&#233;nez"
          "autores" => array:9 [
            0 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Nieblas-Toscano"
            ]
            1 => array:2 [
              "nombre" => "A&#46;J&#46;"
              "apellidos" => "Arenas-Bonilla"
            ]
            2 => array:2 [
              "nombre" => "J&#46;F&#46;"
              "apellidos" => "Flores-Mart&#237;n"
            ]
            3 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Guti&#233;rrez-Tejero"
            ]
            4 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Velarde-Mu&#241;oz"
            ]
            5 => array:2 [
              "nombre" => "C&#46;I&#46;"
              "apellidos" => "Ramos-Alaminos"
            ]
            6 => array:2 [
              "nombre" => "M&#46;C&#46;"
              "apellidos" => "Salas-Moreno"
            ]
            7 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Galisteo-Moya"
            ]
            8 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Moreno-Jim&#233;nez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S021048061930213X"
        "doi" => "10.1016/j.acuro.2019.11.003"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021048061930213X?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578620300202?idApp=UINPBA00004N"
    "url" => "/21735786/0000004400000003/v1_202004300403/S2173578620300202/v1_202004300403/en/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2173578620300135"
    "issn" => "21735786"
    "doi" => "10.1016/j.acuroe.2019.08.007"
    "estado" => "S300"
    "fechaPublicacion" => "2020-04-01"
    "aid" => "1198"
    "copyright" => "AEU"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "cita" => "Actas Urol Esp. 2020;44:148-55"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
      "titulo" => "Magnetic resonance as imaging diagnostic tool in prostate cancer&#58; New evidences-The EAU section of uro-technology position"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "148"
          "paginaFinal" => "155"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "La resonancia magn&#233;tica como herramienta para el diagn&#243;stico del c&#225;ncer de pr&#243;stata&#58; nuevas evidencias y posicionamiento de la ESUT &#40;EAU Section of Uro-Technology&#41;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Fig&#46; 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 675
              "Ancho" => 1667
              "Tamanyo" => 72805
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Fig&#46; "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The use of multiparametric MRI &#40;mpMRI&#41; as a triage test enables all men with negative mpMRI to be spared from receiving a biopsy&#44; opting for a surveillance strategy mainly based on the use of PSA and follow- up mpMRI&#46; &#40;For interpretation of the references to colour in this figure legend&#44; the reader is referred to the web version of this article&#41;&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; &#193;lvarez-Maestro, J&#46; G&#243;mez Rivas, J&#46; Quesada Olarte, D&#46; Carri&#243;n Monsalve, C&#46; Trelles Guzman, C&#46; Ballesteros, L&#46;M&#46; Quintana, A&#46; Aguilera Baz&#225;n, L&#46; Mart&#237;nez-Pi&#241;eiro, E&#46; Liatsikos, E&#46; Barret"
          "autores" => array:11 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "&#193;lvarez-Maestro"
            ]
            1 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "G&#243;mez Rivas"
            ]
            2 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Quesada Olarte"
            ]
            3 => array:2 [
              "nombre" => "D&#46;"
              "apellidos" => "Carri&#243;n Monsalve"
            ]
            4 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Trelles Guzman"
            ]
            5 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Ballesteros"
            ]
            6 => array:2 [
              "nombre" => "L&#46;M&#46;"
              "apellidos" => "Quintana"
            ]
            7 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Aguilera Baz&#225;n"
            ]
            8 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Mart&#237;nez-Pi&#241;eiro"
            ]
            9 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Liatsikos"
            ]
            10 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Barret"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0210480619301639"
        "doi" => "10.1016/j.acuro.2019.08.003"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480619301639?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578620300135?idApp=UINPBA00004N"
    "url" => "/21735786/0000004400000003/v1_202004300403/S2173578620300135/v1_202004300403/en/main.assets"
  ]
  "en" => array:22 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Androgen deprivation therapy in patients with localized disease&#58; Comparison with curative intent treatments and time to castration resistance&#46; Results of the Spanish Prostate Cancer Registry"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "156"
        "paginaFinal" => "163"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "J&#46; Garcia-Rodriguez, J&#46;M&#46; Fernandez-Gomez, J&#46;M&#46; Cozar, B&#46; Mi&#241;ana, F&#46; Gomez-Veiga, A&#46; Rodriguez-Antolin"
        "autores" => array:8 [
          0 => array:4 [
            "nombre" => "J&#46;"
            "apellidos" => "Garcia-Rodriguez"
            "email" => array:1 [
              0 => "jgrmed@hotmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0125"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Fernandez-Gomez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0125"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Cozar"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0130"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "B&#46;"
            "apellidos" => "Mi&#241;ana"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0135"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "F&#46;"
            "apellidos" => "Gomez-Veiga"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0140"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Rodriguez-Antolin"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0145"
              ]
            ]
          ]
          6 => array:2 [
            "colaborador" => "On behalf of Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata &#40;GESCAP&#41;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
          7 => array:1 [
            "colaborador" => "On behalf of Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata &#40;GESCAP&#41;"
          ]
        ]
        "afiliaciones" => array:5 [
          0 => array:3 [
            "entidad" => "Departamento de Urolog&#237;a&#44; Hospital Universitario Central de Asturias&#44; Oviedo&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0125"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Urolog&#237;a&#44; Hospital Virgen de las Nieves&#44; Granada&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0130"
          ]
          2 => array:3 [
            "entidad" => "Departamento de Urolog&#237;a&#44; Hospital Morales Meseguer&#44; Murcia&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0135"
          ]
          3 => array:3 [
            "entidad" => "Departamento de Urolog&#237;a&#44; Hospital Cl&#237;nico&#44; Salamanca&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0140"
          ]
          4 => array:3 [
            "entidad" => "Departamento de Urolog&#237;a&#44; Hospital Universitario 12 de Octubre&#44; Madrid&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0145"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Terapia de privaci&#243;n de andr&#243;genos en pacientes con enfermedad localizada&#58; comparaci&#243;n de las opciones de tratamiento y tiempo hasta la resistencia a la castraci&#243;n&#46; Resultados del Registro Espa&#241;ol de C&#225;ncer de Pr&#243;stata"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 4253
            "Ancho" => 1315
            "Tamanyo" => 332717
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Overall survival according to group &#40;Group 1&#58; with patients with low and intermediate risk clinically localized tumors&#59; Group 2&#58; high risk and locally advanced &#40;T3-4&#41; tumors&#46; Group 3&#58; patients with metastatic tumors&#41;&#46; &#40;b&#41; Cancer-specific survival according to group &#40;Group 1&#58; with patients with low and intermediate risk clinically localized tumors&#59; Group 2&#58; high risk and locally advanced &#40;T3-4&#41; tumors&#46; Group 3&#58; patients with metastatic tumors&#41;&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Androgen deprivation therapy &#40;ADT&#41; is indicated in metastatic prostate cancer and may be also an option in locally advanced tumors unsuitable for surgery or Radiotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">1</span></a> Although ADT is not a therapeutic option in localized tumors&#44;<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">2&#44;3</span></a> it is frequently used in daily practice&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">4</span></a> In this way&#44; ADT was applied in a substantial number of patients with localized prostate cancer in the Spanish Prostate Cancer Registry series on prostate cancer<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">5</span></a> and in other international series of localized prostate cancer&#46;<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">2&#44;6&#44;7</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Some reports have demonstrated an overall survival benefit in patients with localized or locally advanced prostate cancer who undergo ADT&#44; especially in elderly patients with associated morbidities&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">4</span></a> Frequently&#44; high mortality from non-cancer-specific causes occurs in these patients&#46; Age at the onset of ADT&#44; PSA and tumor stage are important factors of overall and cancer-specific survival&#44; being castration resistance the most significant determinant of cancer-specific survival&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">8</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Nevertheless&#44; up to now the effect of primary ADT in patients with localized disease has not been well documented&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">4</span></a> Outcomes of non-metastatic tumors may be different that those of metastatic tumors in patients with prostate cancer treated with ADT&#46;<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">8</span></a> Thus&#44; in the present paper the evolution of tumors treated with ADT as primary therapy in the Spanish Prostate Cancer Registry has been analyzed&#44; comparing the progression of metastatic tumors with those of localized and locally advanced prostate tumors&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Material and methods</span><p id="par0020" class="elsevierStylePara elsevierViewall">In our series&#44; 719 patients treated with ADT as primary treatment &#40;19&#46;4&#37; of the overall Spanish Prostate Cancer Registry&#41; were analyzed&#46; The study protocol was reviewed and approved by the Ethics Committee of the Hospital Virgen de las Nieves &#40;Granada&#41;&#46; Thus&#44; the study was conducted in accordance with the ethical principles of human research of the Declaration of Helsinki and specific informed consent was obtained from each participant&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">To simplify&#44; the series was distributed in balanced groups&#44; including clinically localized tumors and metastatic tumors&#46; For localized tumors the D&#8217;Amico classification was taken into account &#40;low risk&#58; cT1-cT2a and Gleason &#60;7 and PSA &#8804;10<span class="elsevierStyleHsp" style=""></span>ng&#47;ml&#44; intermediate risk&#58; cT2b or Gleason<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>7 or PSA &#62;10 and &#8804;20<span class="elsevierStyleHsp" style=""></span>ng&#47;ml&#59; and high risk&#58; cT2c or PSA &#62;20<span class="elsevierStyleHsp" style=""></span>ng&#47;ml or Gleason &#62;7&#41;&#46; Thus&#44; the overall cohort was classified in three groups&#44; as follows&#58; group 1&#44; with patients with low and intermediate risk clinically localized tumors&#59; group 2&#44; with high risk and locally advanced &#40;T3-4&#41; tumors and&#44; finally&#44; group 3&#44; including patients with metastatic tumors &#40;nodal or bone metastases&#41;&#46; &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">In almost all cases&#44; continuous androgen deprivation &#40;ADT&#41; was used &#40;only 6&#37; of patients received intermittent ADT&#41;&#44; and only 4 patients underwent subalbugineal orchiectomy&#46; The clinical-pathological characteristics &#40;age&#44; T stage&#44; N&#44; M&#44; PSA at diagnosis&#44; and D&#8217;Amico risk group&#41; were studied in non-metastatic tumors treated with ADT&#44; as well as the time from diagnosis to treatment&#44; comparing these parameters with the characteristics of patients with metastatic tumors treated with ADT&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Subsequently&#44; the time to castration resistance &#40;defined as three consecutive PSA elevations separated by at least one week&#44; with two 50&#37; increments over the nadir with PSA greater than 2<span class="elsevierStyleHsp" style=""></span>ng&#47;ml&#44; testosterone levels of less than 50<span class="elsevierStyleHsp" style=""></span>ng&#47;dl or 1&#46;7<span class="elsevierStyleHsp" style=""></span>nmol&#47;l&#44; progression of bone lesions &#8805;2 in bone scintigraphy or progression of soft tissue lesions according to RECIST criteria&#41; and overall cancer-specific survival&#44; both in patients with metastatic and non-metastatic tumors undergoing ADT was analyzed&#46; In addition&#44; in non-metastatic tumors&#44; survival in patients treated with ADT was compared with data taken from patients who underwent local treatments &#40;radical prostatectomy&#44; external beam radiotherapy and brachytherapy&#44; excluding cryotherapy&#44; active surveillance and observation&#41; in the series of the Spanish Prostate Cancer Registry&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">The quantitative variables were described by means of the mean and standard deviation&#44; or by the median and interquartile range &#40;iqr&#41; in case of a non-normal distribution&#46; In the first case &#40;normal distribution&#41; the groups were compared by means of an analysis of the variance&#44; and in the second by the nonparametric Kruskall-Wallis test&#46; For the qualitative variables&#44; the groups were compared using the Ji<span class="elsevierStyleSup">2</span> test from the contingency tables&#46; The Kaplan&#8211;Meier method was used to calculate the survival and the probability of castration resistance&#46; The probability curves for the development of castration resistance and survival were compared by the logrank test&#46; Cox proportional hazard models were used to calculate the hazard ratio associated to each factor&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Results</span><p id="par0045" class="elsevierStylePara elsevierViewall">Finally&#44; 703 cases were analyzed &#40;in 16 patients data were incomplete&#41;&#46; The mean age was 74&#46;4 years&#46; The characteristics of the complete series have been previously published&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">5</span></a> Of the patients treated with ADT&#44; 231 had clinically localized tumors of low- or intermediate-risk of the D&#8217;Amico classification &#40;group 1&#41;&#44; 301 had high-risk or locally advanced tumors &#40;group 2&#41; and 171 metastatic tumors &#40;group 3&#41;&#44; either by nodal or bone involvement&#46; There were no differences in age between groups&#44; although logically there were significant differences in mean PSA at diagnosis &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;0001&#41;&#44; which was very high in the group of metastatic tumors &#40;group 3&#44; mean PSA&#58; 389<span class="elsevierStyleHsp" style=""></span>ng&#47;dl&#41; compared to the other groups &#40;group 1&#58; 10&#46;2<span class="elsevierStyleHsp" style=""></span>ng&#47;dl&#44; group 2&#58; 60&#46;9<span class="elsevierStyleHsp" style=""></span>ng&#47;dl&#41;&#46; Likewise&#44; both the Gleason score distribution of biopsy as and the clinical local stage were related to the corresponding D&#8217;Amico risk group&#46; The use of complete androgen blockade &#40;LHRH agonist with antiandrogens&#41; was significantly higher &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;0007&#41; in patients with metastatic tumors &#40;57&#46;6&#37;&#41; than in group 2 &#40;49&#46;8&#37;&#41; or group 1 &#40;38&#46;8&#37;&#41;&#46; Time to initiation of ADT in group 3 &#40;metastatic&#41; was significantly lower &#40;10 days&#59; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;00001&#41; than in group 2 &#40;month and a half&#41; or in group 1 &#40;2 months&#41;&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">With a median follow-up of 35&#46;8 months &#40;iqr&#58; 18&#46;5<span class="elsevierStyleHsp" style=""></span>m&#41; and a maximum of 39 months&#44; 18&#46;8&#37; of patients &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>132&#41; became castration-resistant&#58; 67&#37; of metastatic tumors&#44; 29&#46;5&#37; in group 2 and only 3&#37; in group 1&#46; Thus&#44; at 3 years after the onset of ADT&#44; only 1&#46;5&#37; of patients in group 1 were castration-resistant compared to 14&#46;9&#37; in group 2 or 55&#46;5&#37; in group 3&#46; The median time until &#8211; castration resistance was 26 months in group 3 &#40;HR&#58; 42&#46;76&#44; 95&#37;CI&#58; 15&#46;69&#8211;116&#46;52&#41;&#46; There were significant differences &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;001&#41; in the time to castration resistance&#44; which was significantly lower in group 3 &#40;metastatic&#41;&#46; Like this&#44; the time to castration resistance was significantly lower in group 3 than in group 2 &#40;HR&#58; 7&#46;6&#44; 95&#37;CI&#58; 2&#46;73&#8211;21&#46;5&#41;&#44; which also was significantly lower than in group 1 &#40;in groups 1 and 2 medians of time to castration resistance were not reached&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Fig&#46; 1</a>&#41;&#46; In the multivariate analysis no independent factors of castration resistance were detected&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0055" class="elsevierStylePara elsevierViewall">During follow-up&#44; there were 179 deaths &#40;25&#46;5&#37;&#41; of which 89 &#40;12&#46;6&#37;&#41; were due to prostate cancer&#46; With a maximum of 39 months of follow-up&#44; the overall mortality was 48&#46;5&#37;&#46; The cancer-specific mortality was 29&#46;5&#37; in the group of metastatic tumors&#44; being higher than in group 2 &#40;overall mortality of 18&#46;9&#37; and cancer-specific mortality of 7&#46;1&#37;&#41; or in group 1 &#40;overall mortality of 16&#46;8&#37; and cancer-specific mortality of 1&#46;3&#37;&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0010">Fig&#46; 2</a>a and b&#41;&#46; Thus&#44; after 3 years of ADT&#44; only 14&#46;6&#37; of patients in group 1 had died &#40;1&#37; due to prostate cancer&#41;&#44; compared to 20&#46;5&#37; in group 2 or 46&#46;8&#37; in group 3 &#40;9&#46;2&#37; and 31&#46;3&#37; due to prostate cancer&#44; respectively&#41;&#46; The median overall survival in metastatic tumors undergoing ADT was 38 months &#40;median not reached in the other groups&#41;&#46; There were significant differences in the overall survival time between the group of metastatic tumors &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;001&#41; and the other 2 groups &#40;HR&#58; 2&#46;99&#59; 95&#37;CI&#44; 2&#46;03&#8211;4&#46;04&#41;&#44; although there were not statistical differences between group 1 and group 2&#46; Cancer-specific mortality was significantly higher in the group of metastatic tumors &#40;group 3&#41; &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;0001&#41;&#44; which was statistically higher than in group 2 &#40;high-risk and locally advanced tumors&#41; &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;01&#41; and than in group 1 &#40;low- or intermediate-risk localized tumors&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">Lastly&#44; overall and cancer-specific survival in groups 1 &#40;low- and intermediate-risk tumors&#41; and 2 &#40;high-risk and locally advanced tumors&#41; treated with ADT were compared with those in patients who underwent local treatment &#40;radical prostatectomy or radiotherapy -external beam radiotherapy and brachytherapy-&#41; in the Spanish Prostate Cancer Registry&#46; In both&#44; group 1 and group 2&#44; overall survival was worse in patients undergoing ADT &#40;<a class="elsevierStyleCrossRef" href="#fig0015">Fig&#46; 3</a>&#41;&#46; Regarding cancer-specific survival&#44; in group 1 was significantly worse using ADT &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;05&#41; than radical prostatectomy or radiotherapy&#44; whose curves practically overlapped &#40;<a class="elsevierStyleCrossRef" href="#fig0020">Fig&#46; 4</a>&#41;&#46; In high-risk and locally advanced tumors &#40;group 2&#41;&#44; ADT also had a lower cancer-specific survival &#40;<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>0&#46;001&#41; than the local treatments &#40;HR&#58; 0&#46;1&#59; 90&#37;CI&#58; 0&#46;025&#8211;0&#46;45 respect to radical prostatectomy and HR&#58; 0&#46;16&#59; 90&#37;CI&#58; 0&#46;072&#8211;0&#46;39 respect to radiotherapy&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0025">Fig&#46; 5</a>&#41;&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="fig0020"></elsevierMultimedia><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Discussion</span><p id="par0065" class="elsevierStylePara elsevierViewall">Although ADT is indicated for the treatment of advanced disease&#44;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">9</span></a> some authors have confirmed that in clinical practice a significant proportion of patients receives ADT as primary treatment for localized disease&#46;<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">4&#44;5&#44;10&#44;11</span></a> Watchful waiting is considered an acceptable approach for many patients with localized well- or moderately differentiated disease&#44; particularly among those with significant comorbidities or those who are hesitant to proceed with radical therapy due to potential side effects&#46; In fact&#44; for many patients expectant management can cause significant anxiety&#44;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">6</span></a> which is associated with a greater probability of receiving active treatment&#46;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">12</span></a> Since ADT is known to provide a decline of prostate-specific antigen &#40;PSA&#41; in about 90&#37; of patients with hormone-na&#239;ve prostate cancer&#44; patients and physicians may perceive ADT as an effective treatment and less invasive than radiation therapy or surgery&#46; Although the time to initiate castration in our series was significantly longer in patients with clinically localized tumors than with metastatic tumors&#44; the onset of ADT was deferred only about 2 months after the diagnosis of localized prostate cancer&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">ADT is the standard of care for patients with biochemical recurrence after definitive primary therapy&#44; locally advanced disease or metastatic disease&#44; but the majority of patients will progress to castration resistant disease &#40;CRPC&#41; within 2&#8211;3 years&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">13</span></a> Different characteristics of PSA variation after starting ADT such as pretreatment PSA level&#44; nadir&#44; time to nadir&#44; and doubling time have clinical significances as prognostic factors to predict CRPC&#46;<a class="elsevierStyleCrossRefs" href="#bib0210"><span class="elsevierStyleSup">14&#8211;19</span></a> However&#44; the accuracy of these patterns as predictors is still unclear and most of them&#44; as PSA nadir or doubling time&#44; may be in fact surrogate markers of cancer behavior&#46; To our knowledge&#44; this is the first study that compare the evolution to CRPC according to different stages of the tumor&#46; In our series&#44; the median of time to castration resistance in metastatic tumors was of 26 months&#44; much lower than in localized or locally advanced tumors&#46; Interestingly&#44; after 3 years of ADT&#44; significant differences in time to castration resistance were found between groups in our series&#46; In this way&#44; only 1&#46;5&#37; of patients with low and intermediate risk localized tumors were resistant to castration compared to 14&#46;9&#37; in the group of high risk localized tumors and locally advanced tumors or 55&#46;5&#37; in the metastatic tumors&#46; During the last decade&#44; numerous studies have shown that despite systemic androgen depletion&#44; AR signaling remains active and supports the survival and growth of cancer cells&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">20</span></a> The progression of CRPC is now known to be due to the onset of a number of resistance mechanisms induced by the selective pressure of endocrine therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">21</span></a> Castration is able to induce clonal selection and subsequent growth of androgen-independent cellular clones&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">22</span></a> However&#44; in spite of current clinical staging limitations&#44; our results suggest that several unknown mechanisms could be present in prostate tumors before castration&#44; even in previous periods of undetectable metastatic disease&#44; which could determine a differential response to ADT and evolution to castration resistance&#46; Therefore&#44; this could be the reason why some patients with hormone-sensitive disease might benefit from chemotherapy in association with endocrine therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">22</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Moreover&#44; ADT can have substantial long-term adverse consequences on the quality and quantity of life&#46;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">23</span></a> These adverse effects include impaired cognitive function&#44; loss of muscle strength&#44; anemia&#44; bone loss or fractures&#44; coronary heart disease&#44; insulin sensitivity and diabetes mellitus&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">24</span></a> Recently&#44; Wong et al&#46; have demonstrated no benefit to primary androgen deprivation therapy and possibly greater mortality&#44; presenting a strong argument against its use as primary therapy in these patients&#44;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">6</span></a> which has been reflected in different guidelines&#46;<a class="elsevierStyleCrossRefs" href="#bib0265"><span class="elsevierStyleSup">25&#44;26</span></a> In the present series&#44; a high mortality rate &#40;greater than 25&#37;&#41; was observed in patients treated with ADT&#44; although more than half of deaths were caused by factors not related to the tumor&#46; Unfortunately&#44; the cause of mortality in patients who did not die from prostate cancer was not registered and therefore&#44; a potential relationship with ADT toxicity could not be established&#46; In addition&#44; probably an important bias in the selection of cases for ADT occurred&#44; including a higher proportion of patients unfit for local treatment in spite of a localized disease&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">In the present study&#44; the mortality from prostate cancer in metastatic tumors was around 30&#37; &#40;the cause of the death in the remaining patients was not analyzed&#41;&#44; being only of 1&#37; in patients with low- and intermediate-risk localized tumors&#44; similar results to those published for watchful waiting&#46;<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">27&#44;28</span></a> However&#44; in the group 2 &#40;localized high risk tumors and locally advanced tumors&#41; the cancer-specific mortality was 7&#46;1&#37;&#46; Compared to the results obtained in patients undergoing local treatments included in the Spanish Registry of Prostate Cancer&#44; significant lower cancer-specific survival was demonstrated in relation to ADT in both groups&#44; i&#46;e&#46;&#44; in low- and intermediate-risk tumors &#40;group 1&#41; and in high-risk and locally advanced tumors &#40;group 2&#41;&#46; These results seems to indicate that ADT is not a sufficient therapy for localized disease&#44; mainly for high risk and locally advanced tumors in which local treatment is required to improve survival&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">14</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">There are several limitations in our study&#46; Because of the retrospective nature of data collection&#44; the limited information about the cause of death in patients who died of non-tumor related causes and a short follow-up period&#44; the statistical results should be interpreted cautiously&#46; However&#44; some clearly significant results were obtained which were provided from a large multicenter series&#46; Therefore&#44; despite these limitations&#44; this series does add important information about the evolution of patients with non-metastatic prostate tumors treated with ADT in the real clinical world&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">In conclusion&#44; a longer time until the castration resistance was observed in patients treated with ADT with well- and intermediate-risk localized tumors than in high risk and locally advanced tumors&#46; Moreover&#44; patients with metastatic tumors shown the shortest time to castration resistance&#46; Consequently&#44; new research is necessary to achieve a better knowledge of the natural history of prostate cancer and to detect aggressive features which probably are already present even in early phases&#46; On the other hand&#44; in patients with non-metastatic tumors&#44; cancer-specific survival was shorter using ADT as primary treatment&#44; especially in the group of high-risk and locally advanced tumors&#44; where local treatment was significantly more effective&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Funding</span><p id="par0095" class="elsevierStylePara elsevierViewall">Astellas Pharma&#44; Inc&#46; is the legal promoter of this study&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1330674"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Background"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Patients and methods"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusion"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1226039"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1330673"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:1 [
              "identificador" => "abst0025"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Pacientes y m&#233;todos"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusi&#243;n"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1226038"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Material and methods"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Results"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Funding"
        ]
        9 => array:2 [
          "identificador" => "xack459582"
          "titulo" => "Acknowledgements"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2018-10-21"
    "fechaAceptado" => "2019-06-09"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1226039"
          "palabras" => array:3 [
            0 => "Androgen deprivation therapy"
            1 => "Localized prostate cancer"
            2 => "Castration resistance"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1226038"
          "palabras" => array:3 [
            0 => "Terapia de privaci&#243;n androg&#233;nica"
            1 => "C&#225;ncer de pr&#243;stata localizado"
            2 => "Resistencia a castraci&#243;n"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The effect of primary androgen deprivation therapy &#40;ADT&#41; in patients with localized prostate cancer &#40;PCa&#41; has not been well documented&#46; The objective of the present study was to analyze the outcome of tumors treated with ADT as primary therapy in the Spanish Prostate Cancer Registry &#40;19&#46;4&#37; of the series&#41;&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Patients and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Patients were classified in three groups&#58; &#40;1&#41; with low&#47;intermediate risk clinically localized tumors&#59; &#40;2&#41; with high risk and locally advanced &#40;T3-4&#41; tumors&#59; &#40;3&#41; with metastatic tumors&#46; Time to castration resistance and overall cancer-specific survival were analyzed&#46; In non-metastatic tumors&#44; survivals in patients treated with ADT were compared with data from patients who underwent local treatments from the Spanish Prostate Cancer Registry&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">703 cases were analyzed&#46; There were significant differences in the time to castration resistance&#44; which was lower in the group of metastatic tumors&#46; During follow-up&#44; there were 179 deaths &#40;25&#46;5&#37;&#41; of which 89 &#40;12&#46;6&#37;&#41; were due to PCa&#46; After 3 years of ADT&#44; only 14&#46;6&#37; of patients in group 1 had died &#40;1&#37; due to PCa&#41;&#44; 20&#46;5&#37; in group 2 and 46&#46;8&#37; in group 3 &#40;9&#46;2&#37; and 31&#46;3&#37; due to PCa&#44; respectively&#41;&#46; Cancer-specific survival was significantly worse in group 1 using ADT than radical prostatectomy or radiotherapy&#46; In high-risk and locally advanced tumors&#44; ADT also had a lower cancer-specific survival than local treatments&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusion</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">A longer time until the castration resistance was observed in patients with well- and intermediate-risk localized tumors treated with ADT&#46; Patients with metastatic tumors showed the shortest time to castration resistance&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Background"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Patients and methods"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusion"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Antecedentes El efecto del tratamiento primario de privaci&#243;n androg&#233;nica &#40;TPA&#41; en pacientes con c&#225;ncer de pr&#243;stata &#40;CP&#41; localizado no est&#225; bien documentado&#46; El objetivo del presente estudio fue analizar el resultado de los tumores tratados con TPA como terapia primaria en el Registro Espa&#241;ol de C&#225;ncer de Pr&#243;stata &#40;19&#44;4&#37; de la serie&#41;&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Pacientes y m&#233;todos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Los pacientes se clasificaron en tres grupos&#58; 1&#41; con tumores cl&#237;nicamente localizados de riesgo bajo&#47;intermedio&#59; 2&#41; con tumores de alto riesgo y localmente avanzados &#40;T3-4&#41;&#59; 3&#41; con tumores metast&#225;sicos&#46; Se analiz&#243; el tiempo hasta la resistencia a la castraci&#243;n y la supervivencia general espec&#237;fica del c&#225;ncer&#46; En tumores no metast&#225;sicos&#44; las supervivencias en pacientes tratados con TPA se compararon con los datos de pacientes que recibieron tratamientos locales del Registro Espa&#241;ol de C&#225;ncer de Pr&#243;stata&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Se analizaron 703 casos&#46; Hubo diferencias significativas en el tiempo de resistencia a la castraci&#243;n&#44; que fue menor en el grupo de tumores metast&#225;sicos&#46; Durante el seguimiento hubo 179 muertes &#40;25&#44;5&#37;&#41;&#44; de las cuales 89 &#40;12&#44;6&#37;&#41; se debieron a CP&#46; Despu&#233;s de 3 a&#241;os de TPA&#44; solo el 14&#44;6&#37; de los pacientes en el grupo 1 fallecieron &#40;1&#37; debido a CP&#41;&#44; el 20&#44;5&#37; en el grupo 2 y el 46&#44;8&#37; en el grupo 3 &#40;9&#44;2&#37; y 31&#44;3&#37; debido a CP&#44; respectivamente&#41;&#46; La supervivencia espec&#237;fica del c&#225;ncer fue significativamente peor en el grupo 1 tratado con TPA que en el que recibi&#243; prostatectom&#237;a radical o radioterapia&#46; En los tumores de alto riesgo y localmente avanzados&#44; la TPA tambi&#233;n tuvo una menor supervivencia espec&#237;fica al c&#225;ncer que los tratamientos locales&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Conclusi&#243;n</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Se observ&#243; un tiempo m&#225;s largo hasta la resistencia a la castraci&#243;n en pacientes con tumores localizados de riesgo intermedio y bien tratados con TPA&#46; Los pacientes con tumores metast&#225;sicos mostraron el menor tiempo hasta la resistencia a la castraci&#243;n&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:1 [
            "identificador" => "abst0025"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Pacientes y m&#233;todos"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusi&#243;n"
          ]
        ]
      ]
    ]
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Garcia-Rodriguez J&#44; Fernandez-Gomez JM&#44; Cozar JM&#44; Mi&#241;ana B&#44; Gomez-Veiga F&#44; Rodriguez-Antolin A&#44; et al&#46; Terapia de privaci&#243;n de andr&#243;genos en pacientes con enfermedad localizada&#58; comparaci&#243;n de las opciones de tratamiento y tiempo hasta la resistencia a la castraci&#243;n&#46; Resultados del Registro Espa&#241;ol de C&#225;ncer de Pr&#243;stata&#46; Actas Urol Esp&#46; 2020&#59;44&#58;156&#8211;163&#46;</p>"
      ]
      1 => array:3 [
        "etiqueta" => "&#9674;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">The researchers participating in the Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata &#40;GESCAP&#41; are listed in <a class="elsevierStyleCrossRef" href="#sec0030">Appendix A</a>&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0105" class="elsevierStylePara elsevierViewall">CHUAC &#40;Paula P&#243;rtela&#44; Eva Blanco&#44; Juan Andr&#233;s Gonz&#225;lez&#41;&#44; Hospital Regional Universitario Carlos Haya &#40;V&#237;ctor Baena&#44; Pedro Morales&#41;&#44; Fundaci&#243;n Puigvert &#40;Humberto Villavicencio&#44; Joan Palou&#41;&#44; H&#46; de Basurto &#40;Ana Loizaga&#41;&#44; H&#46; Cl&#237;nic i Provincial de Barcelona &#40;Alex Ciudin&#44; Diaconau Mihai&#41;&#44; H&#46; Cl&#237;nico Universitario de Valencia &#40;Jos&#233; Mar&#237;a Mart&#237;nez Jabaloyas&#44; Ana Castell&#243;&#44; Nelson D&#237;ez&#41;&#44; H&#46; Cl&#237;nico Universitario Lozano Blesa &#40;Francisco Javier Romero&#44; Jorge Subir&#225;&#44; Ana Isabel Ch&#225;vez&#44; Victoria Capap&#233;&#44; Mar&#237;a Mata&#44; Javier Elizalde&#41;&#44; H&#46; General Universitario de Alicante &#40;Juan Jos&#233; Lobato&#44; Jes&#250;s Jim&#233;nez&#44; Lu&#237;s P&#233;rez Llorca&#44; Juan Antonio Tenza&#41;&#44; H&#46; General Universitario Gregorio Mara&#241;&#243;n &#40;Felipe Herranz&#44; Adri&#225;n Husillos&#44; Esther L&#243;pez&#44; Daniel Ram&#237;rez&#44; Igor Blaha&#41;&#44; H&#46; General Universitario Morales Meseguer &#40;Emilio Izquierdo&#44; Leandro Reina&#41;&#44; H&#46; U&#46; 12 de Octubre &#40;Juan Passas&#44; Laura D&#237;ez&#41;&#44; H&#46; U&#46; Central de Asturias &#40;Miguel A&#46; Hevia&#41;&#44; H&#46; U&#46; de Bellvitge &#40;Manel Castells&#41;&#44; H&#46; U&#46; de Canarias &#40;Tom&#225;s Concepci&#243;n Masip&#44; Ana Cristina Plata&#41;&#44; H&#46; U&#46; Infanta Cristina &#40;Sim&#243;n Asuar Aydillo&#44; Juan Alonso&#44; Jes&#250;s Mateos&#41;&#44; H&#46; U&#46; Puerta de Hierro-Majadahonda &#40;Joaqu&#237;n Carballido&#44; Claudio Mart&#237;nez&#44; Jennifer Areche&#41;&#44; H&#46; U&#46; Ram&#243;n y Cajal &#40;Rafael Rodr&#237;guez&#44; Vital Hevia&#44; Sara &#193;lvarez&#41;&#44; H&#46; U&#46; Reina Sof&#237;a &#40;Mar&#237;a Jos&#233; Requena&#44; Rafael Prieto&#44; Jos&#233; Lu&#237;s Carazo&#44; Javier M&#225;rquez&#44; Enrique G&#243;mez&#44; Jos&#233; Horacio Garc&#237;a&#41;&#44; H&#46; U&#46; R&#237;o Hortega &#40;Jos&#233; Am&#243;n&#44; Marcos Cepeda&#44; Luis &#193;lvarez&#44; Ver&#243;nica Rodr&#237;guez&#44; Beatriz de la Cruz&#44; Alberto Rivero&#44; Juan Francisco S&#225;nchez&#44; Juan Antonio Mainez&#41;&#44; H&#46; U&#46; Virgen del Roc&#237;o &#40;Rafael Medina&#44; Manuel Conde&#41;&#44; H&#46; U&#46; Virgen Macarena &#40;Jes&#250;s Casti&#241;eiras&#44; Antonio Carlos Gonz&#225;lez Baena&#44; Ernesto S&#225;nchez&#44; Rub&#233;n Campanario&#44; Roc&#237;o Saiz&#44; Edwin Romero&#41;&#44; H&#46; U&#46; Vall d&#8217;Hebron &#40;Juan Morote&#44; Carles Xavier Ravent&#243;s&#44; Ana Celma&#41;&#44; H&#46; Virgen de las Nieves &#40;Fernando V&#225;zquez&#41;&#44; H&#46; Virgen de la Salud &#40;Antonio G&#243;mez&#44; Elena Buend&#237;a&#44; Natanael Garc&#237;a&#41;&#46;</p>"
            "etiqueta" => "Appendix A"
            "titulo" => "Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata"
            "identificador" => "sec0030"
          ]
        ]
      ]
    ]
    "multimedia" => array:6 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2634
            "Ancho" => 1591
            "Tamanyo" => 210863
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Probability of castration resistance according to group &#40;Group 1&#58; with patients with low and intermediate risk clinically localized tumors&#59; Group 2&#58; high risk and locally advanced &#40;T3-4&#41; tumors&#46; Group 3&#58; patients with metastatic tumors&#41;&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figure 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 4253
            "Ancho" => 1315
            "Tamanyo" => 332717
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Overall survival according to group &#40;Group 1&#58; with patients with low and intermediate risk clinically localized tumors&#59; Group 2&#58; high risk and locally advanced &#40;T3-4&#41; tumors&#46; Group 3&#58; patients with metastatic tumors&#41;&#46; &#40;b&#41; Cancer-specific survival according to group &#40;Group 1&#58; with patients with low and intermediate risk clinically localized tumors&#59; Group 2&#58; high risk and locally advanced &#40;T3-4&#41; tumors&#46; Group 3&#58; patients with metastatic tumors&#41;&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figure 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 4285
            "Ancho" => 1479
            "Tamanyo" => 301540
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">&#40;a&#41; Overall survival in group 1 &#40;low- and intermediate- localized risk tumors&#41; according to treatment including patients from the Spanish Prostate Cancer Registry&#46; &#40;b&#41; Overall survival in group 2 &#40;high risk localized and locally advanced tumors&#41; according to treatment including patients from the Spanish Prostate Cancer Registry&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figure 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 2430
            "Ancho" => 1511
            "Tamanyo" => 174499
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Cancer-specific survival in group 1 &#40;low- and intermediate- localized risk tumors&#41; according to treatment including patients from the Spanish Prostate Cancer Registry&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figure 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 2403
            "Ancho" => 1519
            "Tamanyo" => 179837
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Cancer-specific survival in group 2 &#40;high risk localized and locally advanced tumors&#41; according to treatment including patients from the Spanish Prostate Cancer Registry&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">ADT&#58; Androgen Deprivation Therapy&#59; EBR and&#47;or BT&#58; External beam radiation and&#47;or brachytherapy&#59; RP&#58; radical Prostatectomy&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Group 1&#58; with patients with low and intermediate risk clinically localized tumors&#59; Group 2&#58; high risk and locally advanced &#40;T3-4&#41; tumors&#46; Group 3&#58; patients with metastatic tumors &#40;nodal or bone metastases&#41;&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Median age&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PSA at diagnosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">PSA at start of treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Gleason &#8804;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Gleason &#62;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#176; positive cores&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#37; T&#8804;T1c&#47;&#8805;T2a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Group 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">231&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">146&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">75&#46;3&#47;24&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Group 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">301&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">252&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30&#46;5&#47;69&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Group 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">171&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">24&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">72&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">100&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">101&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">155&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="char" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#46;7&#47;90&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2280557.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Characteristics of the series according to D&#8217;Amico classification and presence of metastases&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:28 [
            0 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EAU guidelines on prostate cancer Part II&#58; treatment of advanced&#44; relapsing&#44; and castration-resistant prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Heidenreich"
                            1 => "P&#46;J&#46; Bastian"
                            2 => "J&#46; Bellmunt"
                            3 => "M&#46; Bolla"
                            4 => "S&#46; Joniau"
                            5 => "T&#46; van der Kwast"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eururo.2013.11.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Urol"
                        "fecha" => "2014"
                        "volumen" => "65"
                        "paginaInicial" => "467"
                        "paginaFinal" => "479"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24321502"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survival following primary androgen deprivation therapy among men with localized prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;L&#46; Lu-Yao"
                            1 => "P&#46;C&#46; Albertsen"
                            2 => "D&#46;F&#46; Moore"
                            3 => "W&#46; Shih"
                            4 => "Y&#46; Lin"
                            5 => "R&#46;S&#46; DiPaola"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jama.300.2.173"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA"
                        "fecha" => "2008"
                        "volumen" => "300"
                        "paginaInicial" => "173"
                        "paginaFinal" => "181"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18612114"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bicalutamide 150<span class="elsevierStyleHsp" style=""></span>mg plus standard care vs standard care alone for early prostate cancer"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Casodex Early Prostate Cancer Trialists&#8217; Group"
                          "etal" => false
                          "autores" => array:6 [
                            0 => "D&#46;G&#46; McLeod"
                            1 => "P&#46; Iversen"
                            2 => "W&#46;A&#46; See"
                            3 => "T&#46; Morris"
                            4 => "J&#46; Armstrong"
                            5 => "M&#46;P&#46; Wirth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1464-410X.2005.06051.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "BJU Int"
                        "fecha" => "2006"
                        "volumen" => "97"
                        "paginaInicial" => "247"
                        "paginaFinal" => "254"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16430622"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Androgen-deprivation therapy as primary treatment for localized prostate cancer&#58; data from Cancer of the Prostate Strategic Urologic Research Endeavor &#40;CaPSURE&#41;"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "CaPSURE Investigators"
                          "etal" => false
                          "autores" => array:6 [
                            0 => "J&#46; Kawakami"
                            1 => "J&#46;E&#46; Cowan"
                            2 => "E&#46;P&#46; Elkin"
                            3 => "D&#46;M&#46; Latini"
                            4 => "J&#46; DuChane"
                            5 => "P&#46;R&#46; Carroll"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.21799"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2006"
                        "volumen" => "106"
                        "paginaInicial" => "1708"
                        "paginaFinal" => "1714"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16544313"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment trends for clinically localised prostate cancer National population analysis&#58; GESCAP group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46; Minana"
                            1 => "A&#46; Rodriguez-Antolin"
                            2 => "F&#46; Gomez-Veiga"
                            3 => "C&#46; Hern&#225;ndez"
                            4 => "J&#46;F&#46; Su&#225;rez"
                            5 => "J&#46;M&#46; Fern&#225;ndez-G&#243;mez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.acuro.2015.09.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Urol Esp"
                        "fecha" => "2016"
                        "volumen" => "40"
                        "paginaInicial" => "209"
                        "paginaFinal" => "216"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26723895"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The role of primary androgen deprivation therapy in localized prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Y&#46;N&#46; Wong"
                            1 => "S&#46;J&#46; Freedland"
                            2 => "B&#46; Egleston"
                            3 => "N&#46; Vapiwala"
                            4 => "R&#46; Uzzo"
                            5 => "K&#46; Armstrong"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eururo.2009.03.066"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Urol"
                        "fecha" => "2009"
                        "volumen" => "56"
                        "paginaInicial" => "609"
                        "paginaFinal" => "616"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19368995"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluation of data quality in the National Prostate Cancer Register of Sweden"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "K&#46; Tomic"
                            1 => "F&#46; Sandin"
                            2 => "A&#46; Wigertz"
                            3 => "D&#46; Robinson"
                            4 => "M&#46; Lambe"
                            5 => "P&#46; Stattin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2014.10.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2015"
                        "volumen" => "51"
                        "paginaInicial" => "101"
                        "paginaFinal" => "111"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25465187"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer&#58; 20-year single-centre experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;J&#46; DiBlasio"
                            1 => "J&#46;B&#46; Malcolm"
                            2 => "J&#46; Hammett"
                            3 => "J&#46;Y&#46; Wan"
                            4 => "M&#46;A&#46; Aleman"
                            5 => "A&#46;L&#46; Patterson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1464-410X.2009.08593.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "BJU Int"
                        "fecha" => "2009"
                        "volumen" => "104"
                        "paginaInicial" => "1208"
                        "paginaFinal" => "1214"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19388987"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Contemporary role of androgen deprivation therapy for prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Pagliarulo"
                            1 => "S&#46; Bracarda"
                            2 => "M&#46;A&#46; Eisenberger"
                            3 => "N&#46; Mottet"
                            4 => "F&#46;H&#46; Schr&#246;der"
                            5 => "C&#46;N&#46; Sternberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eururo.2011.08.026"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Urol"
                        "fecha" => "2012"
                        "volumen" => "61"
                        "paginaInicial" => "11"
                        "paginaFinal" => "25"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21871711"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Guideline-discordant androgen deprivation therapy in localized prostate cancer&#58; patterns of use in the medicare population and cost implications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46;R&#46; Kuykendal"
                            1 => "L&#46;H&#46; Hendrix"
                            2 => "R&#46;G&#46; Salloum"
                            3 => "P&#46;A&#46; Godley"
                            4 => "R&#46;C&#46; Chen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/annonc/mds618"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Oncol"
                        "fecha" => "2013"
                        "volumen" => "24"
                        "paginaInicial" => "1338"
                        "paginaFinal" => "1343"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23277483"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Determinants of androgen deprivation therapy use for prostate cancer&#58; role of the urologist"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "V&#46;B&#46; Shahinian"
                            1 => "Y&#46;F&#46; Kuo"
                            2 => "J&#46;L&#46; Freeman"
                            3 => "J&#46;S&#46; Goodwin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/jnci/djj230"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Natl Cancer Inst"
                        "fecha" => "2006"
                        "volumen" => "98"
                        "paginaInicial" => "839"
                        "paginaFinal" => "845"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16788157"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;M&#46; Latini"
                            1 => "S&#46;L&#46; Hart"
                            2 => "S&#46;J&#46; Knight"
                            3 => "J&#46;E&#46; Cowan"
                            4 => "P&#46;L&#46; Ross"
                            5 => "J&#46; Duchane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.juro.2007.05.039"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Urol"
                        "fecha" => "2007"
                        "volumen" => "178"
                        "paginaInicial" => "826"
                        "paginaFinal" => "831"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17632144"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Androgen deprivation therapy&#58; progress in understanding mechanisms of resistance and optimizing androgen depletion"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "W&#46;P&#46; Harris"
                            1 => "E&#46;A&#46; Mostaghel"
                            2 => "P&#46;S&#46; Nelson"
                            3 => "B&#46; Montgomery"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ncpuro1296"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Clin Pract Urol"
                        "fecha" => "2009"
                        "volumen" => "6"
                        "paginaInicial" => "76"
                        "paginaFinal" => "85"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19198621"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "Y&#46;H&#46; Park"
                            1 => "I&#46;S&#46; Hwang"
                            2 => "C&#46;W&#46; Jeong"
                            3 => "H&#46;H&#46; Kim"
                            4 => "S&#46;E&#46; Lee"
                            5 => "C&#46; Kwak"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.juro.2009.01.104"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Urol"
                        "fecha" => "2009"
                        "volumen" => "181"
                        "paginaInicial" => "2520"
                        "paginaFinal" => "2524"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19371894"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46; Kwak"
                            1 => "S&#46;J&#46; Jeong"
                            2 => "M&#46;S&#46; Park"
                            3 => "E&#46; Lee"
                            4 => "S&#46;E&#46; Lee"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/01.ju.0000024925.67014.21"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Urol"
                        "fecha" => "2002"
                        "volumen" => "168"
                        "paginaInicial" => "995"
                        "paginaFinal" => "1000"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12187207"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J&#46; Morote"
                            1 => "E&#46; Trilla"
                            2 => "S&#46; Esquena"
                            3 => "J&#46;M&#46; Abascal"
                            4 => "J&#46; Reventos"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ijc.11639"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Cancer"
                        "fecha" => "2004"
                        "volumen" => "108"
                        "paginaInicial" => "877"
                        "paginaFinal" => "881"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14712491"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer&#58; data from Southwest Oncology Group Trial 9346 &#40;INT-0162&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Hussain"
                            1 => "C&#46;M&#46; Tangen"
                            2 => "C&#46; Higano"
                            3 => "P&#46;F&#46; Schelhammer"
                            4 => "J&#46; Faulkner"
                            5 => "E&#46;D&#46; Crawford"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2006.06.4246"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2006"
                        "volumen" => "24"
                        "paginaInicial" => "3984"
                        "paginaFinal" => "3990"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16921051"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Time to an undetectable prostate-specific antigen &#40;PSA&#41; after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "A&#46;V&#46; D&#8217;Amico"
                            1 => "D&#46;G&#46; McLeod"
                            2 => "P&#46;R&#46; Carroll"
                            3 => "J&#46; Cullen"
                            4 => "M&#46;H&#46; Chen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.22550"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2007"
                        "volumen" => "109"
                        "paginaInicial" => "1290"
                        "paginaFinal" => "1295"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17315162"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;K&#46; Choueiri"
                            1 => "W&#46; Xie"
                            2 => "A&#46;V&#46; D&#8217;Amico"
                            3 => "R&#46;W&#46; Ross"
                            4 => "J&#46;C&#46; Hu"
                            5 => "M&#46; Pomerantz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.24064"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2009"
                        "volumen" => "115"
                        "paginaInicial" => "981"
                        "paginaFinal" => "987"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19152438"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "T&#46; Karantanos"
                            1 => "C&#46;P&#46; Evans"
                            2 => "B&#46; Tombal"
                            3 => "T&#46;C&#46; Thompson"
                            4 => "R&#46; Montironi"
                            5 => "W&#46;B&#46; Isaacs"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eururo.2014.09.049"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Urol"
                        "fecha" => "2015"
                        "volumen" => "67"
                        "paginaInicial" => "470"
                        "paginaFinal" => "479"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25306226"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer&#58; a systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Tucci"
                            1 => "V&#46; Bertaglia"
                            2 => "F&#46; Vignani"
                            3 => "C&#46; Buttigliero"
                            4 => "C&#46; Fiori"
                            5 => "F&#46; Porpiglia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eururo.2015.09.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Urol"
                        "fecha" => "2016"
                        "volumen" => "69"
                        "paginaInicial" => "563"
                        "paginaFinal" => "573"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26422676"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Adaptation and clonal selection models of castration-resistant prostate cancer&#58; current perspective"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; Ahmed"
                            1 => "L&#46;C&#46; Li"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/iju.12005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Urol"
                        "fecha" => "2013"
                        "volumen" => "20"
                        "paginaInicial" => "362"
                        "paginaFinal" => "371"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23163774"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiovascular mortality in patients with prostate cancer exposed to androgen deprivation therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;I&#46; Monzo-Gardiner"
                            1 => "F&#46; Herranz-Amo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.acuro.2015.01.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Urol Esp"
                        "fecha" => "2015"
                        "volumen" => "39"
                        "paginaInicial" => "518"
                        "paginaFinal" => "522"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25726508"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46;L&#46; Potosky"
                            1 => "R&#46; Haque"
                            2 => "A&#46;E&#46; Cassidy-Bushrow"
                            3 => "M&#46; Ulcickas Yood"
                            4 => "M&#46; Jiang"
                            5 => "H&#46;T&#46; Tsai"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2013.52.5782"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2014"
                        "volumen" => "32"
                        "paginaInicial" => "1324"
                        "paginaFinal" => "1330"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24638009"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The 2010 NCCN clinical practice guidelines in oncology on prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46;L&#46; Mohler"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.6004/jnccn.2010.0010"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Natl Compr Canc Netw"
                        "fecha" => "2010"
                        "volumen" => "8"
                        "paginaInicial" => "145"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20141674"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EAU-ESTRO-SIOG Guidelines on Prostate Cancer&#46; Part II&#58; Treatment of relapsing metastatic&#44; and castration-resistant prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Cornford"
                            1 => "J&#46; Bellmunt"
                            2 => "M&#46; Bolla"
                            3 => "E&#46; Briers"
                            4 => "M&#46; De Santis"
                            5 => "T&#46; Gross"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.eururo.2016.08.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Urol"
                        "fecha" => "2017"
                        "volumen" => "71"
                        "paginaInicial" => "630"
                        "paginaFinal" => "642"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27591931"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Radical prostatectomy or watchful waiting in early prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Bill-Axelson"
                            1 => "L&#46; Holmberg"
                            2 => "H&#46; Garmo"
                            3 => "J&#46;R&#46; Rider"
                            4 => "K&#46; Taari"
                            5 => "C&#46; Busch"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1311593"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2014"
                        "volumen" => "370"
                        "paginaInicial" => "932"
                        "paginaFinal" => "942"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24597866"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Radical prostatectomy versus observation for localized prostate cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46;J&#46; Wilt"
                            1 => "M&#46;K&#46; Brawer"
                            2 => "K&#46;M&#46; Jones"
                            3 => "M&#46;J&#46; Barry"
                            4 => "W&#46;J&#46; Aronson"
                            5 => "S&#46; Fox"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa1113162"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2012"
                        "volumen" => "367"
                        "paginaInicial" => "203"
                        "paginaFinal" => "213"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22808955"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack459582"
        "titulo" => "Acknowledgements"
        "texto" => "<p id="par0100" class="elsevierStylePara elsevierViewall">The authors would like to acknowledge all the participating investigators as a GESCAP Group &#40;Grupo Espa&#241;ol de C&#225;ncer de Pr&#243;stata&#41; listed in <a class="elsevierStyleCrossRef" href="#sec0030">Appendix A</a>&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735786/0000004400000003/v1_202004300403/S2173578620300214/v1_202004300403/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6274"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735786/0000004400000003/v1_202004300403/S2173578620300214/v1_202004300403/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578620300214?idApp=UINPBA00004N"
]
Article information
ISSN: 21735786
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2021 December 1 2 3

Follow this link to access the full text of the article

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos